Search
forLearn
5 / 801 resultslearn Setipiprant
learn Prednisolone
learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
Research
5 / 89 resultsresearch Oxidative DNA Damage Accelerates Skin Inflammation in Pristane-Induced Lupus Model
Loss of OGG1 increases skin inflammation and auto-antibodies in lupus.
research LO-010 Relationship between the EULAR/ACR classification criteria and organ damage in systemic lupus erythematosus
Higher EULAR/ACR scores in SLE patients predict more organ damage.
research Differential impact of environmental factors on systemic and localized autoimmunity
Environmental factors like diet and vitamin levels, especially Vitamin D, can affect autoimmune diseases differently, with lifestyle changes potentially improving outcomes.
research Stem cell activity shapes the pleiotropic effects of IFN-γ and TGF-β in autoimmune diseases, infections, and cancer, and drives autoimmune flares and remissions
Stem cell activity influences autoimmune disease outcomes by affecting immune responses and tissue regeneration.
research Newborn infant skin gene expression: Remarkable differences versus adults
Newborn skin is uniquely prepared to adapt to new environments compared to adult skin.
Community Join
5 / 1000+ resultscommunity UPDATE: The theory that explains everything. Please help me make this big!
Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.
community Dental technician is convinced that he has found the cause of pattern hair loss
A dental technician claims malocclusion causes pattern hair loss due to poor scalp circulation. Users debate this, noting treatments like finasteride, minoxidil, and microneedling focus on DHT and blood flow.
community The story of RU58841/PSK3841
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
community Ru58841 and pyrilutamid receptor binding affinity vs spironolactone?
Female considering adding topical anti-androgen, seeks advice on RU58841 or pyrilutamid's binding affinity compared to spironolactone.
community Setipiprant trial results
Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.